Viatris (VTRS): MYL PR on Tecfidera patent win: https...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	828
Posts	119591
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: None

Thursday, 06/18/2020 4:24:02 PM

Thursday, June 18, 2020 4:24:02 PM

MYL PR on Tecfidera patent win:

https://www.prnewswire.com/news-releases/mylan-wins-district-court-decision-against-biogens-tecfidera-patent-301079843.html

Mylan N.V. today announced that the U.S. District Court for the Northern District of West Virginia invalidated Biogen's Tecfidera patent, U.S. Patent No. 8,399,514, for lack of written description. The ?514 patent claimed methods of treating multiple sclerosis (MS) using a dose of 480 mg/day of dimethyl fumarate delayed release capsules.

Today's decision clears the way for Mylan's launch of its dimethyl fumarate product upon the receipt of FDA approval. The '514 patent could have otherwise delayed generic competition until 2028.

This decision is modestly bullish for PFE shareholders on account of the pending Viatris deal.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”